• Rosemary-Root Lignans and Anti-Inflammatory Activity

  2026-10-08

  A January 2026 Fitoterapia study characterized eight lignans and four phenylpropanoids from Rosmarinus officinalis roots, including three previously unreported rosmarinicols. In an LPS-stimulated RAW264.7 macrophage model, six compounds reduced nitric oxide production, supporting rosemary roots as a source for further natural-product anti-inflammatory research while leaving mechanism, selectivity, and translational relevance unresolved.

• HyperScript™ Reverse Transcriptase for cDNA

  2026-10-08

  HyperScript™ Reverse Transcriptase is a genetically engineered M-MLV Reverse Transcriptase derivative described for RNA-to-cDNA conversion, including templates with complex secondary structure. The product dossier lists cDNA products up to 12.3 kb, but the supplied sources do not establish independent comparative performance or a validated clinical application.

• Ethacridine Lactate Monohydrate: Evidence and Scope

  2026-10-07

  Ethacridine lactate monohydrate is examined through an evidence-centered lens for biochemical and cellular research. This article connects its supplier-reported properties with the 2026 YAP–TEAD surface ectoderm study while distinguishing microbial control claims from biological interpretation.

• Thiazovivin Product Overview and Evidence Limits

  2026-10-07

  Thiazovivin (A5506) is a supplier-described ROCK inhibitor for conceptual stem cell research applications. No matched paper evidence was provided, so performance, mechanism, and applicability cannot be independently assessed here.

• Thiazovivin Product Overview and Evidence Limits

  2026-10-06

  Thiazovivin (SKU A5506) is a supplier-described ROCK inhibitor for stem cell research. No matched paper evidence was provided, so its reported research applications remain unverified within this overview.

• Lopinavir: What Cross-Viral Evidence Really Shows

  2026-10-06

  Lopinavir and ABT-378 are best understood through the relationship between molecular potency, cellular antiviral activity, and evidence provenance. This article examines HIV protease research and the MERS-CoV screening study without overstating what cross-viral findings demonstrate.

• Caspase-3 Fluorometric Assay Kit in Apoptosis Research

  2026-10-05

  A source-grounded overview of DEVD-dependent caspase activity detection, its relevance to apoptosis research, and how the Caspase-3 Fluorometric Assay Kit can be interpreted alongside orthogonal evidence. The discussion emphasizes the findings of Yao et al. in renal cell carcinoma, assay specificity, evidence strength, and applicability limits.

• HyperPFU™ High-Fidelity DNA Polymerase: Evidence

  2026-10-05

  Explore how HyperPFU high-fidelity DNA polymerase supports sequence-accurate analysis of difficult DNA, including GC-rich and long templates. This evidence-focused article connects polymerase fidelity with interpretation of recent base-editing research while defining important applicability limits.

• WZ4003: Interpreting NUAK1/2 Evidence

  2026-10-04

  WZ4003 is a NUAK1/2 inhibitor that connects kinase signaling with cell-cycle, migration, invasion, and tau biology. This evidence-led analysis focuses on how model differences and biomarker choice shape interpretation of its value in cancer research and neurodegeneration.

• LY364947 and TGF-β Signaling: Reading EMT Evidence

  2026-10-03

  Explore how LY364947, a TGF-β type I receptor kinase inhibitor, can frame mechanistic questions about Smad signaling, EMT, and the Wnt/β-catenin pathway. This evidence-focused analysis distinguishes established findings from hypotheses inspired by recent pancreatic cancer research.

• α-Bungarotoxin for Nicotinic Receptor Blockade

  2026-10-01

  Use α-Bungarotoxin to convert α7 receptor involvement from a correlation into a testable pharmacological hypothesis. This workflow connects receptor blockade with cholinergic signaling, necroptosis, inflammation, and trophoblast function while providing practical controls for neuroscience and translational assays.

• TH287 MTH1 Inhibitor for Radiosensitization

  2026-10-01

  TH287 converts MTH1-dependent nucleotide sanitization into a controllable cancer-cell stress model, with particular value in ionizing-radiation studies. A timing-focused workflow helps researchers examine oxidative DNA damage, apoptosis, cell-cycle arrest, and radiosensitization in castration-resistant prostate cancer models.

• Bestatin, Actinonin, and Intracellular Myeloma Effects

  2026-09-30

  The reference study challenges the assumption that bestatin and actinonin inhibit proliferation mainly by blocking cell-surface aminopeptidases. By combining proliferation assays with efflux-modifier experiments, it supports a model in which intracellular drug exposure and transporter activity are central determinants of response.

• Fingolimod (FTY720) in T-Cell Trafficking Assays

  2026-09-30

  Fingolimod (FTY720) provides a controllable way to interrogate S1P-dependent lymphocyte trafficking alongside magnetically guided CAR-T-mimicking cell platforms. This workflow-focused guide separates egress inhibition, T-cell activation, tumor-cell toxicity, and CNS signaling so combination experiments remain interpretable rather than assuming improved tumor infiltration.

• Ampicillin Sodium: Mechanism and Research Use

  2026-09-29

  Ampicillin sodium is a β-lactam antibiotic used to study bacterial cell wall biosynthesis inhibition and antibacterial activity. The A2510 product is reported at 98% purity, with product-dossier benchmarks of 1.8 μg/mL against transpeptidase in E. coli 146 cells and a 3.1 μg/mL MIC.

8700 records 1/580 page Next 12345 下5页 Last page